LXEO Stock — Lexeo Therapeutics Inc.: Cash, EV, Pipeline

Share price

$4.20

Market cap

$344.6M

Cash

$211.7M

Enterprise value

$132.9M

Balance sheet

Cash	$211.7M
Debt	$0.0M
Net cash	$211.7M
Enterprise value	$132.9M
Basic shares	78.6M shares
Fully diluted shares	115.1M shares
Fully diluted market cap	$483.6M
Cash per share	$2.69

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading LXEO daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 12 - Feb 23	LX2020	Phase 1/2	Arrhythmogenic Cardiomyopathy; PKP2-ACM; PKP2-ARVC	—
Dec 13, 2028 - Jan 24, 2029	LX1001	Phase 1	Alzheimer Disease	—
Oct 13 - Nov 24	Low dose LX2006	Phase 1/2	Friedreich Ataxia; Cardiomyopathy, Secondary	—
Jul 13 - Aug 24	LX2006	Phase 2	Friedreich Ataxia; Cardiomyopathy, Secondary	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

LX2006

Stage not disclosed · Active Modality: AAVrh10-based gene therapy (intravenous)

Target frataxin (FXN)

Partnerships Adverum: exclusive license for FA cardiomyopathy materials/technology (Jan 2021; $7.5M upfront); Cornell: license agreements (May 2020) and investigator-initiated trial

Indications

Friedreich ataxia (FA) cardiomyopathy (Stage not disclosed)

Catalysts

— first half of 2028

Status note SUNRISE-FA Phase 1/2 ongoing; SUNRISE-FA 2 pivotal study initiated Jun 2026 with protocol/SAP finalized incorporating FDA feedback, intended to support BLA under accelerated approval.

LX2020

Phase 1 · Active Modality: AAV-based gene therapy (one-time intravenous infusion)

Target PKP2 (plakophilin-2)

Partnerships Stelios Therapeutics: acquired Jul 2021 (AAV gene therapies for ACM and TNNI3-HCM); up to $12.5M remaining development milestones

Indications

Arrhythmogenic cardiomyopathy caused by PKP2 mutations (PKP2-ACM) (Phase 1)

Status note HEROIC-PKP2 first-in-human, 52-week open-label dose-ascending trial; 10 participants dosed; interim clinical data update Jan 2026.

Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	LX2006
Lead indication	Friedreich Ataxia
Lead phase	Phase 2
Active trials	7

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07721025	Phase 2	Recruiting	Sponsor	Lexeo Therapeutics	—	Friedreich Ataxia; Cardiomyopathy, Secondary	—
NCT06109181	Phase 1/2	Active, not recruiting	Sponsor	Lexeo Therapeutics	—	Arrhythmogenic Cardiomyopathy; PKP2-ACM; PKP2-ARVC	—
NCT05445323	Phase 1/2	Active, not recruiting	Sponsor	Lexeo Therapeutics	—	Friedreich Ataxia; Cardiomyopathy, Secondary	—
NCT05400330	Phase 1	Active, not recruiting	Sponsor	Lexeo Therapeutics	—	Alzheimer Disease	—
NCT06976606	Not disclosed	Recruiting	Sponsor	Lexeo Therapeutics	—	Arrhythmogenic Cardiomyopathy; PKP2-ACM; PKP2-ARVC	—
NCT06865482	Not disclosed	Recruiting	Sponsor	Lexeo Therapeutics	—	Friedreich Ataxia; Cardiomyopathy	—
NCT07050160	Not disclosed	Enrolling by invitation	Sponsor	Lexeo Therapeutics	—	Arrhythmogenic Cardiomyopathy; PKP2-ACM; PKP2-ARVC	—

Sponsor-matched active trials from ClinicalTrials.gov (7 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 7 active trials for Lexeo Therapeutics on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Frazier Life Sciences	4,824,725	+400,000	0.49%	2026-08-14
OrbiMed Advisors	3,947,850	+345,400	0.35%	2026-08-14
ADAR1 Capital Management	1,565,950	+98,600	0.34%	2026-08-14
Ikarian Capital	513,011	no change	0.39%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

LXEO — Lexeo Therapeutics Inc.